Should You Buy BioMarin Pharmaceutical Before Feb. 18?

Core Viewpoint - BioMarin Pharmaceutical is expected to report its Q4 and full-year 2025 results soon, with potential strong performance from its rare-disease drug Voxzogo, but there are also concerns regarding competition and revenue guidance [1][2][3][10]. Financial Performance - BioMarin's CFO indicated that Voxzogo revenue is projected to reach its highest level in Q4, contributing to an optimistic outlook for the quarter [2]. - The company raised the lower end of its 2025 revenue guidance to $3.15 billion, reflecting double-digit year-over-year growth expectations [3]. Upcoming Catalysts - The FDA has set a PDUFA date of February 28, 2026, for Palynziq's approval for adolescents with phenylketonuria, with potential EU approval also expected in the first half of the year [4]. - BioMarin plans to announce results from two Phase 3 clinical studies in the first half of 2026 and intends to file for full FDA approval of Voxzogo for achondroplasia [5]. Market Data - BioMarin's current market capitalization is $11 billion, with a gross margin of 80.64% [7]. - The stock is currently trading at $56.51, with a day's range of $55.30 to $56.72 [6][7]. Investment Considerations - There are reasons to be cautious, including reliance on large contracted ex-U.S. orders for Voxzogo, which if not fulfilled, could lead to missing Q4 estimates [8]. - Long-term uncertainty exists regarding Voxzogo's market position due to potential competition, which could impact future revenue projections [9]. - The acquisition of Amicus Therapeutics is seen as a potential growth booster, but waiting to invest may be prudent given current uncertainties [10].